Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT01600924
Unknown Observational

Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes

NCT01600924 · tracked via the Priya Life Science Italy tracker
Sponsor
Metabolic Fitness Association, Italy
Phase
Observational
Started
2016-09
Last updated
2024-03-22

Condition(s) studied

Type 1 DiabetesType 2 Diabetes

Study summary

This project will assess the independent predictors of impaired muscle and bone strength through a longitudinal observation of a cohort of subjects with type 1 and 2 diabetes consecutively attending an outpatients diabetes clinics for the annual screening of complications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with type 1 or 2 diabetes Exclusion Criteria: * Patients with any condition precluding mobility

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Rome La Sapienza, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Diabetes Unit Rome RM

Other trials for the same condition

Intervention on New Onset-T1D Children Recruiting
E-Health Literacy Intervention for Bangladeshi Migrants With Type 2 Diabetes in Italy Active, not recruiting
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV) Active, not recruiting
JACARDI: A eHealth and Health Literacy Educational Training to Support Older Patients With Type II Diabetes Recruiting
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01600924 on ClinicalTrials.gov ↗ ← All trials in Italy